Our pioneering semiconductor sequencing technology is poised

to bring patients the benefits of fast and insightful diagnostics.

- SEQ

Diagnostic solutions  using fast and powerful genomic analyses.

 

DNAe is developing LiDia-SEQ™, a direct-from-specimen platform that performs DNA sequencing on a microchip, to provide rapid, actionable information to clinicians. The user-friendly system can operate in a variety of hospital environments at the point-of-need, with flexible levels of throughput to match a wide range of clinical demands.

 

Our initial focus is on infectious disease diagnostics, where speed and microbial DNA sequence information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis

 

To follow this, we have a growing pipeline of tests for other healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious diseases and cancer testing and monitoring.

 

 

 

INFECTIOUS DISEASE AND ANTIMICROBIAL RESISTANCE .

 

There is a growing urgency to tackle the alarming rise of antimicrobial resistance (AMR). Strong focus is being placed on reducing the overuse and misdirected use of antibiotics. Capable of rapidly diagnosing infections and associated AMR at the point-of-need, our LiDia-SEQ™ sequencing system and BSI/AMR test is uniquely positioned to respond to this challenge.

 

In September 2016, DNAe was awarded a contract worth up to $51.9M by the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response in the US Health and Human Services, to develop its semiconductor sequencing diagnostic platform initially for antimicrobial resistant infections. We reported successful completion of the first phase of development in late 2018 and are now approaching completion of the second phase.

LIDIA-SEQ IS UNIQUELY POSITIONED

TO RESPOND TO THE THREAT OF

ANTIMICROBIAL RESISTANCE

identify the infection faster

DNAe’s BSI/AMR test

Results in 3-4 hours

Traditional blood culture test

Results in 2-6 days

It can take 2-6 days to diagnose bloodstream infections using a blood culture test. Using our LiDia-SEQ™ sequencing system and BSI/AMR test, this can be achieved in approximately 3-4 hours, directly from raw specimens.

Bringing Cutting Edge Technology to the Patient

 

We have pioneered the use of semiconductor sequencing to build a simple-to-use diagnostic platform that delivers rapid results direct-from-specimen. Our LiDia-SEQ™ system performs genomic analysis on a microchip

For Research Use Only. Not for use in diagnostic procedures

Work with us

AND BEGIN A FASCINATING

JOURNEY OF DISCOVERY

 

We’re creating something radically different – products that change the game for early diagnosis and monitoring of potentially fatal diseases. The work we do at DNAe could potentially save lives and this is a powerful motivator and a wonderful reason to get involved.

 

 

US Careers

 

UK Careers

 

 

COMPANY DETAILS

 

Email: contact@dnae.com

Switchboard: +44 (0)20 7036 2100

Twitter: @dna_electronics

OFFICE  LOCATIONS

DNAe Group Holdings Ltd

Ugli Campus Block C

56 Wood Lane

London

W12 7SB

United Kingdom

 

Google map

DNA Electronics, Inc.

1891 Rutherford Road

Suite 100

Carlsbad, CA 92008

USA

+1 (760) 444-9410

 

Google map

KEEP IN TOUCH

Submitting Form...

The server encountered an error.

Thank you for joining our mailing list

© 2020 DNA Electronics    Privacy & Cookies | Terms of Use | Modern Slavery Statement